Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries.
Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing.
Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets. Lonza Custom Manufacturing offers the life sciences market a full range of bioresearch products, development services and manufacturing for functional and active ingredients.
For 30 years Lonza has been helping emerging and established companies increase product quality, improve production processes, navigate the development and regulatory process, lower the cost of goods, get to market faster, and focus on their core competencies.
From early development through launch to commercial leadership and mature market supply, Lonza’s complete development services, industry-leading manufacturing processes, broad technology platform and lifecycle management experience can help take your product to the next level.
As one of the frontrunners in the contract manufacture of monoclonal antibodies and recombinant proteins from mammalian cell culture, Lonza produces the essential ingredients for tomorrow’s life-saving medicines with four state-of-the-art cGMP multi-product facilities.
One of these facilities is in the UK in the Thames Valley technology corridor, which focuses on process development and clinical trial supply (including small-scale manufacture of licensed products). The second is in the USA, just outside Boston, Massachusetts, focusing on large-scale manufacture for late-stage clinical trials and in-market supply.
The third is in Northern Spain, and the fourth is currently under construction in Singapore. We are hard at work developing the world’s most advanced biotechnology manufacturing processes. Lonza is able to provide a complete development package, taking a product from vector construction and cell line development through to commercial-scale manufacture, including a full range of analytical services and regulatory support for clinical trials and in-market supply. Our customers may request Lonza to perform the complete development program or individual work packages.
A Highly Efficient Mammalian Expression System
Lonza’s powerful proprietary GS System™ uses a robust viral promoter and selection via glutamine metabolism to provide rapid development of high-yielding and stable mammalian cell lines. The GS System™ is successfully used by over 85 global pharmaceutical and biotechnology companies and is familiar to all authorities. Five products have been approved which use the GS System™ including Zenapax® (Roche) and Synagis® (Medimmune).
The international use of the GS System™ by both commercial organisations and academic institutions has lead to a large body of published information. New users can draw upon this material to expand their knowledge and skill base and improve their use of the GS System™.
Lonza has itself created hundreds of cell lines using the GS System ™, many of which have been grown at large-scale and produced product for use in clinical trials and in-market supply. Other GS System™ users have also accumulated experience with a diverse range of products where high yields have been achieved.
Many investigators use the GS System™, not only to develop a manufacturing process, but as a tool to create recombinant proteins for biological studies. The reliability of the GS System™, as a consistent means of rapidly generating high-producing cell lines, speeds time to market.
The associated web pages review the GS System™ and its key advantages, frequently asked questions and related news.
Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries.
